For instance, EZH2 inhibitors have been applied to clinical trials in lymphoma and are suggested as promising therapeutic strategy in MM in combination with IMiDs [8] and proteasome inhibitors [67]. The gene discussed is EZH2; the disease is Miyoshi myopathy.